Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin

BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel classified oral anti-diabetic drugs for the treatment of type 2 diabetes mellitus (T2DM) that provide important reduction in glycated hemoglobin, with a low risk for hypoglycemia and no weight gain. In T2DM patients with reduced renal f...

Descripción completa

Detalles Bibliográficos
Autores principales: Russo, Eleonora, Penno, Giuseppe, Prato, Stefano Del
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639752/
https://www.ncbi.nlm.nih.gov/pubmed/23650450
http://dx.doi.org/10.2147/DMSO.S28951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639752/
https://www.ncbi.nlm.nih.gov/pubmed/23650450
http://dx.doi.org/10.2147/DMSO.S28951

Ejemplares similares